Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cidofovir
Drug ID BADD_D00463
Description Cidofovir is an injectable antiviral medication employed in the treatment of cytomegalovirus (CMV) retinitis in patients diagnosed with AIDS. It suppresses CMV replication through selective inhibition of viral DNA synthesis.[FDA label] It was manufactured by _Gilead_ and initially approved by the FDA in 1996, but has since been discontinued.[L6223]
Indications and Usage For the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS)
Marketing Status Prescription; Discontinued
ATC Code J05AB12
DrugBank ID DB00369
KEGG ID C06909
MeSH ID D000077404
PubChem ID 60613
TTD Drug ID D04AAW
NDC Product Code 48954-728
Synonyms Cidofovir | HPMPC | GS 504 | GS-504 | GS504 | Cidofovir, Sodium Salt | Cidofovir Sodium | Cidofovir, (R)-isomer | Cidofovir Anhydrous | 1-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine | 1-((3-Hydroxy-2-phosphonylmethoxy)propyl)cytosine | Vistide | Cidofovir, (+-)-isomer
Chemical Information
Molecular Formula C8H14N3O6P
CAS Registry Number 113852-37-2
SMILES C1=CN(C(=O)N=C1N)CC(CO)OCP(=O)(O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
ApoptosisPre-mRNA-processing factor 19Q9UMS4Not Available11697818; 10338155; 11948417
ApoptosisCellular tumor antigen p53P04637T1573911697818; 10338155; 11948417
ApoptosisPutative cyclin-dependent kinase inhibitor 1A (P21/WAF1/CIP1)Q683K8Not Available11697818; 10338155; 11948417
ApoptosisCaspase-3P42574T5794311697818; 10338155; 11948417
Nephropathy toxicSolute carrier family 22 member 6Q4U2R8Not Available10462545; 10703662; 10991954
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Abnormal dreams19.02.03.001; 17.15.02.001--Not Available
Acne23.02.01.001--Not Available
Acquired immunodeficiency syndrome11.05.17.007; 10.03.03.001--Not Available
Adrenal insufficiency14.11.01.004; 05.01.02.001--
Agitation19.06.02.001; 17.02.05.012--
Alanine aminotransferase increased13.03.01.003--
Alopecia23.02.02.001--
Amblyopia06.02.01.001--Not Available
Aminoaciduria20.02.01.024; 14.14.04.003; 03.08.04.003--Not Available
Amnesia19.20.01.001; 17.03.02.001--
Anaemia01.03.02.001--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Angioedema23.04.01.001; 10.01.05.009--Not Available
Anorectal disorder07.03.01.001--Not Available
Anxiety19.06.02.002--
Aphthous ulcer07.05.06.002--Not Available
Aplastic anaemia01.03.03.002--Not Available
Arthralgia15.01.02.001--
Arthropathy15.01.01.003--Not Available
Aspartate aminotransferase increased13.03.01.006--
Asthenia08.01.01.001--Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Ataxia17.02.02.001; 08.01.02.004--
Back pain15.03.04.005--
Blindness06.02.02.001; 17.17.01.003--Not Available
Blood bicarbonate decreased13.11.01.019--
Blood creatinine decreased13.13.01.003--Not Available
Blood creatinine increased13.13.01.004--
Blood lactate dehydrogenase increased13.04.02.002--
The 1th Page    1 2 3 4 5    Next   Last    Total 10 Pages